Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 2/20 | 0.61 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.46 |
| ▸ | WDR5 | P61964 | 1/20 | 0.41 |
| ▸ | ALDH1A3 | P47895 | 3/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 2/20 | 0.35 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.35 |
| ▸ | BCL2 | P10415 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11491065 | 0.83 | SCN5A (0.66) | SCN5ADNMT1ALDH1A3MAPK14CYP1A2 | |
| SCHEMBL11140124 | 0.80 | CYP1A2 (0.56) | SCN5ADNMT1WDR5ALDH1A3CYP1A2 | |
| SCHEMBL11476887 | 0.77 | SCN5A (0.58) | SCN5ADNMT1ALDH1A3MAPK14TGFBR1 | |
| SCHEMBL937590 | 0.77 | SCN5A (0.62) | SCN5ADNMT1ALDH1A3MAPK14TGFBR1 | |
| SCHEMBL24460393 | 0.76 | DYRK1A (0.59) | WDR5ALDH1A3CYP1A2TGFBR1FDPS | |
| SCHEMBL11379662 | 0.75 | SCN5A (0.59) | SCN5ADNMT1ALDH1A3MAPK14TGFBR1 | |
| SCHEMBL11384331 | 0.74 | MAPK14 (0.64) | SCN5ADNMT1ALDH1A3MAPK14TGFBR1 | |
| SCHEMBL11474506 | 0.74 | SCN5A (0.58) | SCN5ADNMT1ALDH1A3MAPK14TGFBR1 | |
| SCHEMBL11486274 | 0.74 | SCN5A (0.58) | SCN5ADNMT1ALDH1A3MAPK14TGFBR1 | |
| SCHEMBL11475951 | 0.73 | SCN5A (0.57) | SCN5ADNMT1MAPK14TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220281825-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2022-09-08 | — | — | US | disclosed |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | ARISAN THERAPEUTICS INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | ARISAN THERAPEUTICS INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-10 | — | — | US | disclosed |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-10 | — | — | US | disclosed |
| WO-2018013430-A2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281825-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | C9, C1S, ZC3HAV1 | SCN5A 2024/4885DNMT1 3378/4885WDR5 3258/4885 |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | C9, C1R, C1S | SCN5A 2389/4885DNMT1 3167/4885WDR5 3465/4885 |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | C9, C1R, C1S | SCN5A 2389/4885DNMT1 3167/4885WDR5 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.